Search Results - "EWING, N. P."

Prophylactic treatment with activated prothrombin complex concentrate (FEIBA®) reduces the frequency of bleeding episodes in paediatric patients with haemophilia A and inhibitors by LEISSINGER, C. A., BECTON, D. L., EWING, N. P., VALENTINO, L. A.

“…Orthopaedic complications are among the most disabling sequelae occurring in patients with haemophilia and inhibitors. Recurrent or refractory joint bleeds can…”
Get full text

Understanding FVIII/VWF complex - report from a symposium of XXIX WFH meeting 2010 by GRINGERI, A., OFOSU, F. A., GRANCHA, S., OLDENBURG, J., EWING, N. P., FEDERICI, A. B.

“…von Willebrand factor (VWF) has the capacity to form a complex with factor VIII (FVIII) which may modulate the immunogenicity of FVIII. It has been proposed…”
Get full text

Determination of the Gas-Phase Basicities of Proline and its Di- and Tripeptides with Glycine: The Enhanced Basicity of Prolylproline by Ewing, Nigel P., Zhang, Xin, Cassady, Carolyn J.

“…The gas‐phase basicity (GB) of proline, which is the only imino acid and is reported to play a significant role in protein folding, was determined by…”
Get full text

Induction of immune tolerance, the future of the Registry by Ewing, N P

“…Factor VIII (FVIII) inhibitors are IgG antibodies that neutralize the procoagulant activity of FVIII, rendering hemorrhages difficult to manage. There may…”
Get more information

Dissociation of multiply charged negative ions for hirudin (54–65), fibrinopeptide B, and insulin A (oxidized) by Ewing, Nigel P, Cassady, Carolyn J

“…Collision-induced dissociation (CID) was performed on multiply deprotonated ions from three commercial peptides: hirudin (54–65), fibrinopeptide B, and…”
Get full text

A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A by Peyvandi, Flora, Mannucci, Pier M, Garagiola, Isabella, El-Beshlawy, Amal, Elalfy, Mohsen, Ramanan, Vijay, Eshghi, Peyman, Hanagavadi, Suresh, Varadarajan, Ramabadran, Karimi, Mehran, Manglani, Mamta V, Ross, Cecil, Young, Guy, Seth, Tulika, Apte, Shashikant, Nayak, Dinesh M, Santagostino, Elena, Mancuso, Maria Elisa, Sandoval Gonzalez, Adriana C, Mahlangu, Johnny N, Bonanad Boix, Santiago, Cerqueira, Monica, Ewing, Nadia P, Male, Christoph, Owaidah, Tarek, Soto Arellano, Veronica, Kobrinsky, Nathan L, Majumdar, Suvankar, Perez Garrido, Rosario, Sachdeva, Anupam, Simpson, Mindy, Thomas, Mathew, Zanon, Ezio, Antmen, Bulent, Kavakli, Kaan, Manco-Johnson, Marilyn J, Martinez, Monica, Marzouka, Esperanza, Mazzucconi, Maria G, Neme, Daniela, Palomo Bravo, Angeles, Paredes Aguilera, Rogelio, Prezotti, Alessandra, Schmitt, Klaus, Wicklund, Brian M, Zulfikar, Bulent, Rosendaal, Frits R

“…In a randomized, multicenter trial involving boys with severe hemophilia A, the incidence of neutralizing antibodies to factor VIII was 87% higher with…”
Get full text

Induction of immune tolerance with factor VIII concentrate in patients with hemophilia A and inhibitors by Ewing, N P

Get more information

Therapeutic choices for patients with hemophilia and high‐titer inhibitors by Kulkarni, Roshni, Aledort, Louis M., Berntorp, Erik, Brackman, Hans H., Brown, Deborah, Cohen, Alan R., Ewing, Nadia P., Gringeri, Alessandro, Gruppo, Ralph, Hoots, Keith, Leissenger, Cindy, Peerlinck, Katheliijne, Poon, Man‐Chiu, Wong, Wing‐Yen

“…Effective treatment of bleeding episodes in hemophilia with high titer inhibitors (HTI) remains a challenge, despite the fact that the therapeutic…”
Get full text

Gas-phase basicities for ions from bradykinin and its des-arginine analogues by Ewing, Nigel P., Pallante, Giovanni A., Zhang, Xin, Cassady, Carolyn J.

“…Apparent gas‐phase basicities (GBapps) for [M + H]+ of bradykinin, des‐Arg1‐bradykinin and des‐Arg9‐bradykinin have been assigned by deprotonation reactions of…”
Get full text

Timing and severity of inhibitor development in recombinant versus plasma‐derived factor VIII concentrates: a SIPPET analysis by Peyvandi, F., Cannavò, A., Garagiola, I., Palla, R., Mannucci, P. M., Rosendaal, F. R., El‐Beshlawy, A., Elalfy, M., Ramanan, V., Eshghi, P., Hanagavadi, S., Varadarajan, R., Karimi, M., Manglani, M. V., Ross, C., Young, G., Seth, T., Apte, S., Nayak, D. M., Santagostino, E., Elisa Mancuso, M., Sandoval Gonzalez, A. C., Mahlangu, J. N., Bonanad Boix, S., Cerqueira, M., Ewing, N. P., Male, C., Owaidah, T., Soto Arellano, V., Kobrinsky, N. L., Majumdar, S., Perez Garrido, R., Sachdeva, A., Simpson, M., Thomas, M., Zanon, E., Antmen, B., Kavakl, K., Manco‐Johnson, M. J., Martinez, M., Marzouka, E., Mazzucconi, M. G., Neme, D., Palomo Bravo, A., Paredes Aguilera, R., Prezotti, A., Schmitt, K., Wicklund, B. M., Zulfikar, B.

“…Essentials Recombinant factor VIII (rFVIII) was contrasted with plasma‐derived FVIII (pdFVIII). In previously untreated patients with hemophilia A, rFVIII led…”
Get full text

Prediction of factor VIII inhibitor development in the SIPPET cohort by mutational analysis and factor VIII antigen measurement by Spena, S., Garagiola, I., Cannavò, A., Mortarino, M., Mannucci, P. M., Rosendaal, F. R., Peyvandi, F., El‐Beshlawy, A., Elalfy, M., Ramanan, V., Eshghi, P., Hanagavadi, S., Varadarajan, R., Karimi, M., Manglani, M. V., Ross, C., Young, G., Seth, T., Apte, S., Nayak, D. M., Santagostino, E., Mancuso, M. E., Sandoval Gonzalez, A. C., Mahlangu, J. N., Bonanad Boix, S., Cerqueira, M., Ewing, N. P., Male, C., Owaidah, T., Soto Arellano, V., Kobrinsky, N. L., Majumdar, S., Perez Garrido, R., Sachdeva, A., Simpson, M., Thomas, M., Zanon, E., Antmen, B., Kavakli, K., Manco‐Johnson, M. J., Martinez, M., Marzouka, E., Mazzucconi, M. G., Neme, D., Palomo Bravo, A., Paredes Aguilera, R., Prezotti, A., Schmitt, K., Wicklund, B. M., Zulfikar, B.

“…Essentials A residual factor VIII synthesis is likely to be protective towards inhibitor (INH) development. Mutation type‐inhibitor risk association was…”
Get full text

Induction of Immune Tolerance to Factor VIII in Hemophiliacs With Inhibitors by Ewing, Nadia P, Sanders, Natalie L, Dietrich, Shelby L, Kasper, Carol K

“…Induction of immune tolerance in patients with severe hemophilia A and inhibitors to factor VIII was attempted by daily infusion of 50 U of factor VIII per…”
Get full text

Comparative efficacy of nonheated and heat-treated factor IX complex concentrate in treatment of hemophiliacs with inhibitors by Schwartz, R S, Ewing, N P, Gorenc, T J, Spero, J A

“…To determine if heat-treated factor IX complex concentrate is as effective as nonheated factor IX complex concentrate for treatment of subjects with hemophilia…”
Get more information

The Malmo International Brother Study (MIBS). Genetic defects and inhibitor development in siblings with severe hemophilia A by Astermark, J, Oldenburg, J, Escobar, M, White, GC, 2nd, Berntorp, E, Malmo International Brother Study study group

“…Department for Coagulation Disorders University Hospital SE-205 02 Malmo, Sweden. Jan.astermark@medforsk.mas.lu.se BACKGROUND AND OBJECTIVES: The strongest…”
Get full text

The Malmö International Brother Study (MIBS): further support for genetic predisposition to inhibitor development by Astermark, J., Berntorp, E., White, G. C., Kroner, B. L.

“…The issue of factors predisposing for inhibitor development in haemophilia patients is still largely unresolved. In an attempt to address this problem, we…”
Get full text

Immune tolerance in hemophilia with factor VIII inhibitors: predictors of success by Mariani, G, Kroner, B, Immune Tolerance Study Group (ITSG)

“…Hematology and BMT Unit, Palermo University Hospital, Italy. guglielmo.mariani@tin.it BACKGROUND AND OBJECTIVES: Long term administration of high doses of…”
Get full text

In vitro detection of mild inhibitors to factor VIII in hemophilia by Ewing, N P, Kasper, C K

“…Plasma samples from patients with severe classic hemophilia, suspected of having mild inhibitors not detected in the standard Bethesda inhibitor test, were…”
Get more information

Transfusion of multiple units of Js(b+) red blood cells in the presence of anti-Jsb in a patient with sickle beta-thalassemia disease and a review of the literature by Yuan, S, Ewing, N P, Bailey, D, Salvador, M, Wang, S

“…Jsb is a high-frequency antigen. Anti-Jsb is a rare alloantibody, and its clinical significance is poorly documented. We report a case in which a 12-year-old…”
Get more information

Effects of cysteic acid groups on the gas-phase reactivity and dissociation of [M + 4H] 4+ ions from insulin chain B by Ewing, Nigel P., Cassady, Carolyn J.

“…Gas-phase ion/molecule reactions and collision-induced dissociation (CID) were conducted on [M + 4H] 4+ of insulin chain B. This Fourier transform mass…”
Get full text

Immunetolerance as treatment of alloantibodies to factor VIII in hemophilia. The International Registry of Immunetolerance Protocols by Mariani, G, Scheibel, E, Nogao, T, Kasper, C K, Ewing, N P, Mauser-Bunschoten, E, Ghirardini, A, Bellocco, R, Brackman, H H

Get more information